Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21

Fate Therapeutics Inc FATE has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma.
Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
The company said that interim Phase I data for FT516 revealed eight of 11 patients as of the March cutoff date had achieved an objective response, including six who hit levels of complete response.
Four of the patients came from the second dose cohort, while the other seven came from the third dose cohort.
The company now plans to initiate multiple indication-specific, dose-expansion cohorts for patients with B-cell lymphomas to assess FT516 in combination with CD20-targeted monoclonal antibody regimens.
No dose-limiting toxicities nor severe treatment-related side effects above Grade 3 were observed.
Price Action: FATE shares are up 8.19% at $72.76 during the market session on the last check Friday.